Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaneck Pharmaceutical ETF (PPH)

Vaneck Pharmaceutical ETF (PPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Van Eck Associates
  • Assets Under Management 1,234,167,900
  • Shares Outstanding, K 12,390
  • 60-Month Beta 0.54
  • Price/Earnings ttm 21.89
  • Annual Dividend & Yield 1.94 (1.94%)
  • Most Recent Dividend 0.393 on 10/01/25
  • Management Fee 0.36%
  • INDUSTRY GROUPING:

    ETFs - Healthcare

Options Overview Details

View History
  • Implied Volatility 20.05% (+0.18%)
  • Historical Volatility 16.55%
  • IV Percentile 77%
  • IV Rank 37.25%
  • IV High 33.54% on 04/08/25
  • IV Low 12.03% on 01/21/25
  • Expected Move (DTE 11) 2.18 (2.20%)
  • Put/Call Vol Ratio 13.00
  • Today's Volume 14
  • Volume Avg (30-Day) 118
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 2,421
  • Open Int (30-Day) 1,884
  • Expected Range 96.72 to 101.08

Price Performance

See More
Period Period Low Period High Performance
1-Month
94.24 +4.96%
on 11/10/25
103.56 -4.49%
on 11/26/25
+5.02 (+5.35%)
since 11/07/25
3-Month
85.91 +15.13%
on 09/25/25
103.56 -4.49%
on 11/26/25
+9.91 (+11.13%)
since 09/08/25
52-Week
77.67 +27.35%
on 04/09/25
103.56 -4.49%
on 11/26/25
+8.67 (+9.61%)
since 12/06/24

Most Recent Stories

More News
Cencora Stock: Is Wall Street Bullish or Bearish?

Pharma distributor Cencora has continued to outpace the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

$SPX : 6,838.06 (-0.47%)
COR : 337.23 (-0.72%)
PPH : 98.93 (-0.68%)
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease....

NVO : 46.89 (-2.03%)
OZEM : 33.96 (+4.63%)
PPH : 98.93 (-0.68%)
THNR : 24.95 (-1.07%)
Cencora Stock: Analyst Estimates & Ratings

Cencora has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.

$SPX : 6,838.06 (-0.47%)
JPM : 314.28 (-0.24%)
COR : 337.23 (-0.72%)
PPH : 98.93 (-0.68%)
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs....

NVO : 46.89 (-2.03%)
OZEM : 33.96 (+4.63%)
IHE : 83.59 (+0.63%)
LLY : 995.58 (-1.46%)
MEDX : 33.43 (-0.20%)
PPH : 98.93 (-0.68%)
MEDI : 31.22 (-1.74%)
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue...

XLV : 151.91 (-0.88%)
JNJ : 202.34 (+0.20%)
IHE : 83.59 (+0.63%)
IYH : 64.25 (-0.91%)
PPH : 98.93 (-0.68%)
FTXH : 32.39 (-0.44%)
Do Wall Street Analysts Like Cencora Stock?

Cencora has significantly outperformed the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

$SPX : 6,838.06 (-0.47%)
COR : 337.23 (-0.72%)
PPH : 98.93 (-0.68%)
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

VSS : 143.23 (-0.38%)
VXUS : 75.15 (-0.31%)
PPH : 98.93 (-0.68%)
BLCO : 16.68 (-0.83%)
BHC : 6.95 (+0.29%)
Cencora Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Cencora's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's future.

$SPX : 6,838.06 (-0.47%)
COR : 337.23 (-0.72%)
PPH : 98.93 (-0.68%)
Is Wall Street Bullish or Bearish on AbbVie Stock?

Despite AbbVie's underperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock's future.

$SPX : 6,838.06 (-0.47%)
PPH : 98.93 (-0.68%)
ABBV : 225.40 (-0.30%)
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss medicine...

OZEM : 33.96 (+4.63%)
IHE : 83.59 (+0.63%)
LLY : 995.58 (-1.46%)
MEDX : 33.43 (-0.20%)
PPH : 98.93 (-0.68%)
THNR : 24.95 (-1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The VanEck Vectors Pharmaceutical ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical...

See More

Key Turning Points

3rd Resistance Point 101.47
2nd Resistance Point 101.04
1st Resistance Point 100.33
Last Price 98.93
1st Support Level 99.19
2nd Support Level 98.76
3rd Support Level 98.05

See More

52-Week High 103.56
Last Price 98.93
Fibonacci 61.8% 93.67
Fibonacci 50% 90.61
Fibonacci 38.2% 87.56
52-Week Low 77.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar